Hewei Cheng1, Lu Gao2, Bo Hou3, Feng Feng3, Xiaopeng Guo2, Zihao Wang2, Ming Feng2, Bing Xing4, Yong Fan5. 1. Department of Biomedical Engineering, School of Bioinformatics, Chongqing University of Posts and Telecommunications, Chongqing, PR China; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA; Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. 2. Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; China Pituitary Disease Registry Center, China Pituitary Adenoma Specialist Council, Beijing, PR China. 3. Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China. 4. Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; China Pituitary Disease Registry Center, China Pituitary Adenoma Specialist Council, Beijing, PR China. Electronic address: xingbingemail@aliyun.com. 5. Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA; Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. Electronic address: yong.fan@pennmedicine.upenn.edu.
Abstract
BACKGROUND AND OBJECTIVES: Cushing's disease (CD) patients have metabolic abnormalities in the brain caused by excessive exposure to endogenous cortisol. However, the reversibility of brain metabolism of CD patients after treatment remains largely unknown. METHODS: This study recruited 50 CD patients seeking treatment and 34 matched normal controls (NCs). The patients were treated with Transsphenoidal Adenomectomy (TSA) and reexamined 3 months later. Cerebral blood flow (CBF) of the patients was assessed using 3D pseudo-continuous arterial spin labelling (PCASL) imaging before the treatment and at the 3-month follow-up and were compared with CBF measure of the NCs using a whole-brain voxelwise group comparison method. For remitted patients, their CBF measures and hormone level measures, including adrenocorticotropic hormone (ACTH), 24-hour urinary free cortisol (24hUFC) and serum cortisol, were compared before and after the treatment. Finally, a correlation analysis was carried out to explore the relationship between changes of CBF and hormone level measures of the remitted CD patients. RESULTS: After the treatment, 45 patients reached remission. Compared with the NCs, the CD patients before the treatment exhibited significantly reduced CBF in cortical regions, including occipital lobe, parietal lobe, superior/middle/inferior temporal gyrus, superior/middle/inferior frontal gyrus, orbitofrontal cortex, precentral gyrus, middle/posterior cingulate gyrus, and rolandic operculum, as well as significantly increased CBF in subcortical structures, including caudate, pallidum, putamen, limbic lobe, parahippocampal gyrus, hippocampus, thalamus, and amygdala (p < 0.01, false discovery rate corrected). For the remitted patients, the change in CBF before and after the treatment displayed a spatial pattern similar to the difference between the NCs and the CD patients before the treatment, and no significant difference in CBF was observed between the NCs and the remitted CD patients after the treatment. The changes of 24hUFC were significantly correlated with the changes of averaged CBF within the subcortical region in the remitted patients (p = 0.01). CONCLUSIONS: Our findings demonstrate that the brain metabolic abnormalities of CD patients are reversible when their hormone level changes towards normal after surgery treatment.
BACKGROUND AND OBJECTIVES:Cushing's disease (CD) patients have metabolic abnormalities in the brain caused by excessive exposure to endogenous cortisol. However, the reversibility of brain metabolism of CDpatients after treatment remains largely unknown. METHODS: This study recruited 50 CDpatients seeking treatment and 34 matched normal controls (NCs). The patients were treated with Transsphenoidal Adenomectomy (TSA) and reexamined 3 months later. Cerebral blood flow (CBF) of the patients was assessed using 3D pseudo-continuous arterial spin labelling (PCASL) imaging before the treatment and at the 3-month follow-up and were compared with CBF measure of the NCs using a whole-brain voxelwise group comparison method. For remitted patients, their CBF measures and hormone level measures, including adrenocorticotropic hormone (ACTH), 24-hour urinary free cortisol (24hUFC) and serum cortisol, were compared before and after the treatment. Finally, a correlation analysis was carried out to explore the relationship between changes of CBF and hormone level measures of the remitted CDpatients. RESULTS: After the treatment, 45 patients reached remission. Compared with the NCs, the CDpatients before the treatment exhibited significantly reduced CBF in cortical regions, including occipital lobe, parietal lobe, superior/middle/inferior temporal gyrus, superior/middle/inferior frontal gyrus, orbitofrontal cortex, precentral gyrus, middle/posterior cingulate gyrus, and rolandic operculum, as well as significantly increased CBF in subcortical structures, including caudate, pallidum, putamen, limbic lobe, parahippocampal gyrus, hippocampus, thalamus, and amygdala (p < 0.01, false discovery rate corrected). For the remitted patients, the change in CBF before and after the treatment displayed a spatial pattern similar to the difference between the NCs and the CDpatients before the treatment, and no significant difference in CBF was observed between the NCs and the remitted CDpatients after the treatment. The changes of 24hUFC were significantly correlated with the changes of averaged CBF within the subcortical region in the remitted patients (p = 0.01). CONCLUSIONS: Our findings demonstrate that the brain metabolic abnormalities of CDpatients are reversible when their hormone level changes towards normal after surgery treatment.
Authors: P Pires; A Santos; Y Vives-Gilabert; S M Webb; A Sainz-Ruiz; E Resmini; I Crespo; M de Juan-Delago; B Gómez-Anson Journal: AJNR Am J Neuroradiol Date: 2015-04-30 Impact factor: 3.825
Authors: Oskar Ragnarsson; Andreas Stomby; Per Dahlqvist; Johan A Evang; Mats Ryberg; Tommy Olsson; Jens Bollerslev; Lars Nyberg; Gudmundur Johannsson Journal: Psychoneuroendocrinology Date: 2017-05-12 Impact factor: 4.905
Authors: Guofan Xu; Howard A Rowley; Gaohong Wu; David C Alsop; Ajit Shankaranarayanan; Maritza Dowling; Bradley T Christian; Terrence R Oakes; Sterling C Johnson Journal: NMR Biomed Date: 2010-04 Impact factor: 4.044
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: Steven J A van der Werff; Cornelie D Andela; J Nienke Pannekoek; Onno C Meijer; Mark A van Buchem; Serge A R B Rombouts; Roos C van der Mast; Nienke R Biermasz; Alberto M Pereira; Nic J A van der Wee Journal: Neuroimage Clin Date: 2014-02-10 Impact factor: 4.881